Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-13), Gensight Biologics's Beta is 0.1666.
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Gensight Biologics Beta Related Terms
Gensight Biologics Beta Historical Data
* Premium members only.
The historical data trend for Gensight Biologics's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gensight Biologics's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics Beta vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's Beta distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Gensight Biologics (STU:G49N) has a Beta of 0.1666 as of Sep. 13, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Gensight Biologics and its competitors.
Is Gensight Biologics' Beta too high?
Gensight Biologics' current Beta is 0.1666. Overall, Gensight Biologics has a GF Score™ of 7/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gensight Biologics' Beta compare to VRTX and REGN?
Gensight Biologics' Beta of 0.1666 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Gensight Biologics and its competitors. Gensight Biologics's current Beta is 0.1666. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (STU:G49N) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.10 — trading 160% above its estimated fair value. The current Beta is 0.1666. Gensight Biologics' overall GF Score™ is 7/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Gensight Biologics (STU:G49N), the current Beta is 0.1666 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gensight Biologics (STU:G49N) Overvalued in 2026?
Based on GuruFocus' analysis, Gensight Biologics stock appears to be overvalued.
The current stock price of €0.10 is trading 160% above its estimated GF Value™ of €0.04.
GuruFocus considers Gensight Biologics to be Significantly Overvalued.
Key valuation signals for STU:G49N:
Beta: 0.1666
GF Value™: €0.04 vs. price of €0.10 (160% above fair value)
No single metric tells the full story. See the STU:G49N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
7GF Score
Get the complete analysis for STU:G49N
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:G49N has been successfully added to your 
